$1.51
0.66% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US75062E1064
Symbol
RFL
Sector
Industry

Rafael Holdings Inc - Ordinary Shares - Class B Stock price

$1.51
+0.00 0.00% 1M
-0.19 11.18% 6M
-0.32 17.49% YTD
-0.68 31.05% 1Y
-39.00 96.27% 3Y
-17.96 92.24% 5Y
-3.39 69.18% 10Y
NYSE, Closing price Fri, Sep 06 2024
-0.01 0.66%
ISIN
US75062E1064
Symbol
RFL
Sector
Industry

Key metrics

Market capitalization $37.31m
Enterprise Value $-28.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.34
EV/Sales (TTM) EV/Sales -52.26
P/S ratio (TTM) P/S ratio 69.09
P/B ratio (TTM) P/B ratio 0.43
Revenue growth (TTM) Revenue growth 92.86%
Revenue (TTM) Revenue $540.00k
EBIT (operating result TTM) EBIT $-11.53m
Free Cash Flow (TTM) Free Cash Flow $-6.50m
Cash position $72.38m
EPS (TTM) EPS $-1.21
Short interest 0.20%
Show more

Is Rafael Holdings Inc - Ordinary Shares - Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Rafael Holdings Inc - Ordinary Shares - Class B Stock Analysis

Unlock Scores for Free

Financial data from Rafael Holdings Inc - Ordinary Shares - Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '24
+/-
%
0.54 0.54
93% 93%
100%
- Direct Costs 0.26 0.26
225% 225%
48%
0.28 0.28
40% 40%
52%
- Selling and Administrative Expenses 7.74 7.74
26% 26%
1,433%
- Research and Development Expense 3.89 3.89
44% 44%
720%
-11 -11
34% 34%
-2,104%
- Depreciation and Amortization 0.18 0.18
125% 125%
33%
EBIT (Operating Income) EBIT -12 -12
33% 33%
-2,136%
Net Profit -29 -29
96% 96%
-5,330%

In millions USD.

Don't miss a Thing! We will send you all news about Rafael Holdings Inc - Ordinary Shares - Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rafael Holdings Inc - Ordinary Shares - Class B Stock News

Neutral
GlobeNewsWire
17 days ago
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
Neutral
Business Wire
17 days ago
NEWARK, N.J. & GAINESVILLE, Fla.--(BUSINESS WIRE)--Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares ...
Neutral
GlobeNewsWire
3 months ago
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
More Rafael Holdings Inc - Ordinary Shares - Class B News

Company Profile

Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. The Real Estate segment refers to the real estate holdings. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals. The company is headquartered in Newark, NJ.

Head office United States
CEO William Conkling
Employees 14
Founded 2017
Website www.rafaelholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today